Asieris Pharmaceuticals released its 2026 semi‑annual report showing a robust commercial performance despite a volatile market environment. Operating revenue climbed to RMB 155 million, a 19.28% increase year‑on‑year, driven primarily by the launch of CEVIRA® – the world’s first non‑invasive, non‑surgical treatment for high‑grade cervical intraepithelial neoplasia (CIN). After receiving Chinese regulatory approval in March 2026, the product entered the market in June, with the first prescription issued in Beijing on the same day. Within ten days, CEVIRA® was prescribed in 70 hospitals across 30 cities and is now available in more than 150 hospitals nationwide, supported by an exclusive online channel on JD Health. The company has built an omnichannel commercial network centred on public hospitals, deploying over 100 specialists for physician education, medical affairs, and market access, and is leveraging partners to achieve full‑territory coverage.
In addition to CEVIRA®, Asieris highlighted progress in its broader oncology portfolio. Hexvix®, China’s first blue‑light imaging agent for bladder cancer, is paired with the newly approved SYSTEM BLUE cystoscopy system, and a portable single‑use blue‑light flexible cystoscope (APLD‑2304) secured EU CE certification. The pipeline saw several key milestones: the Phase I trial of FGFR2/3 inhibitor APL‑2401 enrolled its first patient; ADC candidates APL‑2501 (CLDN6/9‑ADC) received IND clearance in both China and the United States, with FDA and NMPA approval to start Phase I trials; and APL‑1401 for ulcerative colitis entered an extension study with data expected by year‑end. The company also reported that its Marketing Authorization Application for CEVIRA® has been accepted for review by the European Medicines Agency, marking the start of its international expansion.
)